Bosutinib monohydrate is a small-molecule tyrosine kinase inhibitor belonging to the BCR-ABL and SRC kinase inhibitor class, primarily used in the treatment of chronic myelogenous leukemia (CML). By inhibiting… Read more
Bosutinib monohydrate is a small-molecule tyrosine kinase inhibitor belonging to the BCR-ABL and SRC kinase inhibitor class, primarily used in the treatment of chronic myelogenous leukemia (CML). By inhibiting the ATP-binding site of these kinases, this compound effectively suppresses the proliferation of leukemic cells associated with the Philadelphia chromosome. Laboratories working with this therapeutic agent require high-quality reference standards for rigorous analytical testing, including impurity profiling and method validation. This collection encompasses Bosutinib monohydrate along with its related pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. These materials serve as essential controls for accurate quantification and identification during pharmaceutical development and quality control procedures, ensuring compliance with strict regulatory standards for efficacy and safety in drug analysis.